BOCOM INTL: Raise target price for AKESO (09926) to HK$115, continues to be listed as a key recommended stock in the industry.
The bank stated that the second head-to-head Phase III study of Ivosec was successful and the first self-immunization product was approved, leading to an upward revision of Kangfang Biotech's (09926) revenue forecast for the fiscal years 2025 to 2027 by 0% to 6%.
BOCOM INTL released a research report stating that the second phase III study of ivosidenib was successful, the first self-clearing product was approved, and the revenue forecast for AKESO (09926) for fiscal years 2025 to 2027 was raised by 0% to 6%. At the same time, the sales peak of "Ivosidenib" in mainland China and overseas market through PoS adjustment were adjusted to 6.1 billion RMB and 5.7 billion USD respectively. The target price of H shares was also raised to 115 Hong Kong dollars, with a "buy" rating, continuing to be listed as a key recommendation in the industry.
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
